RAndomized Controlled Trial of a Multiple INtervention proGram to Decrease Heart Failure Rehospitalization
NCT ID: NCT04703504
Last Updated: 2024-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
25 participants
INTERVENTIONAL
2022-07-15
2024-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research Into Factors Determining Participation in 2 Interventions Modifying the Care Pathways of Patients With Heart Failure: PRADO and Telemedicine
NCT05417490
Efficacy of PRADO Heart Failure in Occitania
NCT03396081
Optimizing Treatments for Heart Failure During Hospitalization
NCT05910437
Interest of the Smartphone Application "MonCœur" in the Follow-up of Patients With Heart Failure
NCT04198779
Optimized Medico-pharmaceutical Collaboration in the Drug Management of Patients With Heart Failure
NCT03902028
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This work will create an interventional assistance program to structure the exit consultation in order to optimize treatment, educate patients, ensure the continuity of hospital-city care and improve compliance (reminders) to reduce re-hospitalizations. This program will be carried out by using a computer platform allowing the systematization of output documents and the sending of messages (e-mail / SMS) for making appointments (medical consultations, biologicals sampling) and perfect therapeutic education.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
multi-intervention
* Automatic creation of discharge prescription (personalized checklist of possible therapeutic optimizations generated from clinical data entered into the platform. This checklist will comply with the recommendations on altered left ventricular ejection fraction from European Society of Cardiology 2016.
* Automatic creation of documents for patient:
* Reminder letter to make an appointment with his general practitioner (at 7 days) and cardiologist (1 month) and to report the prescribed blood test.
* Drug prescription.
* Prescription for blood tests (5 days and 25 days before seeing the general practitioner and cardiologist).
* Therapeutic education documents
* Patients will receive numerous messages (SMS / e-mail) in order to 1 / not forget their medical appointments, 2 / not to forget to make and bring back their blood test for the consultation, 3 / to perfect the therapeutic education advice provided previously
Multiple intervention program
Support for patient follow-up assisted by a computer program
Control
Discharge prescription according to the investigator's habits.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multiple intervention program
Support for patient follow-up assisted by a computer program
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Left Ventricular Ejection Fraction ≤ 40%.
Exclusion Criteria
* Acute reversible cause of heart failure.
* Incurable disease (other than heart failure) or estimated life expectancy of less than one year.
* Patient transferred directly to another department or cardiac rehabilitation center.
* Significant cognitive impairment.
* Patient without cell phone or email.
* Linguistic or psychic refusal or inability to sign the informed consent.
* Current participation in a clinical tria
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
French Cardiology Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arnaud GALAT, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Henri Mondor, Créteil
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Paul d'Egine
Champigny-sur-Marne, , France
Hôpital Henri Mondor
Créteil, , France
Hôpital Simone Veil
Eaubonne, , France
Hôpitaux Nord-Ouest de Villefranche
Gleizé, , France
Hôpital Européen Georges Pompidou
Paris, , France
Polyclinique de Poitiers
Poitiers, , France
Centre Cardiologique du Nord
Saint-Denis, , France
Centre Hopsitalier Lucie et Raymond Aubrac
Villeneuve-Saint-Georges, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.